ONERA-HEALTH
3.1.2022 16:02:10 CET | Business Wire | Press release
Onera Health announced today the introduction of its first Onera Biomedical-Lab-on-Chip™. The biomedical sensor system-on-chip acquires and processes multiple biosignals and is designed for a broad range of wearable health applications and devices, offering many solutions and opportunities for innovation in the medical, wellness and fitness space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005188/en/
"We are thrilled to introduce Onera Biomedical-Lab-on-Chip™ in the lead-up to CES 2022 in Las Vegas this week. It's the perfect opportunity to showcase our chip to the wearables ecosystem! Our highly integrated and comprehensive biosignal sensor hub is a unique solution that promises to revolutionize this competitive field. It combines clinical-grade physiological measurements and analysis with ultra-low-power consumption, enabling the development of miniaturized and high-quality wearable devices. Launching this powerful chip as a stand-alone product within our portfolio, not just as part of our innovative Onera diagnostic and monitoring solutions, is yet another exciting step for our company", explains Ruben de Francisco, Founder and CEO of Onera.
The Dutch-American company leveraged from its deep tech roots and close partnership with imec, a world-leading research and innovation hub in nanoelectronics and digital technologies, with the development of the ultra-low-power biosignal chip.
“Seeing Onera bring this ground-breaking system-on-chip to the market is what imec’s unique experience in semiconductor devices for MedTech applications, and our imec ecosystem, is all about - enabling nano- and digital technology innovation that promises a significant impact on the quality of life”, added Rudi Cartuyvels, COO of imec.
Onera Biomedical-Lab-on-Chip™ is a multi-channel sensor readout system with integrated data processing, power management, and interfacing features. It offers a wide range of on-chip biomedical sensor readouts, including 10 readouts for ExG, covering EEG, ECG, EMG, and EOG, 2 bioimpedance readouts, and 2 readouts for photoplethysmography. The data can be processed by on-chip digital filters and accelerators, supported by a powerful ARM Cortex M4f. The chip features several standard wired interfaces such as UART, SPI, I2C, and I2S. The chip fully operates on a single power source which can be anything between 0.8V and 3.6V, since power management is also integrated on-chip. In addition, a large amount of SRAM and embedded FLASH is available, supporting the large number of data streams with accurate data-synchronization as an essential feature.
To support the development and transition to commercialization of Onera’s products, the company has ramped-up hiring recently, including adding to its strong leadership team.
From the 5th to the 8th of January 2022, Onera Health exhibits its Onera STS I Polysomnography Solution and its Onera Biomedical-Lab-on-Chip™ at CES 2022 in Las Vegas, booth 8570 in the LVCC - North Hall.
About Onera
Onera Health is a leader in transforming diagnostics and monitoring. Their breakthrough products and technologies are poised to help millions of people struggling with health ailments and chronic conditions in a variety of medical fields, including sleep, neuro, cardiac and respiratory care, ultimately improving the health and quality of life for patients around the world. The company’s innovative solutions provide comprehensive physiological and health-related data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. For more information, go to www.onerahealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom